Opinion|Videos|January 3, 2025
Team- and System-Based Approaches to Managing LEMS and Ensuring Access
A panelist discusses how comprehensive care coordination between specialists, proactive adverse effect management, and innovative care models can optimize treatment outcomes for Lambert-Eaton myasthenic syndrome (LEMS) patients, particularly those with dual diagnoses like small cell lung cancer (SCLC), while ensuring both clinical effectiveness and cost-efficiency through managed care strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How can health care teams proactively manage adverse effects associated with treatments like amifampridine?
- How can managed care organizations facilitate timely access to LEMS therapies while ensuring cost-effectiveness?
- What strategies can improve communication and coordination between oncologists, neurologists, and pharmacists in managing dual-diagnosis patients?
- What innovative care models have shown promise in improving outcomes for patients with dual diagnoses like SCLC and LEMS?
Advertisement
Related to this article
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
3
Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk
4
Kidney Week 2026 Recap: IgAN Advances, Value-Based Care, CKD Care Gaps
5